- Visibility 17 Views
- Downloads 13 Downloads
- Permissions
- DOI 10.18231/j.ijpo.12902.1759820304
-
CrossMark
Neurological fallout of mycophenolate: A PRES case
- Author Details:
-
Jenny Susan Varghis *
-
Sara Kurien Kodiattu
-
Chepsy C Philip
-
Aakash Chozakade
-
Bobby Abraham
-
Jacob Jesurun R S
Jenny Susan Varghis *
Posterior reversible encephalopathy syndrome (PRES) is a rare, neurological disorder characterized by visual disturbances, altered mental status, seizures, and radiographic evidence of ‘cacogenic’ cerebral edema. It is most often associated with hypertensive crises, renal failure, and immunosuppressive therapies, especially Calcineurin Inhibitors. PRES is a treatable condition with favorable prognosis, if recognized early. It typically presents with headache, seizures, confusion, and visual disturbances like blurred vision or cortical blindness. Symptoms develop rapidly and are often reversible with early treatment. We report a rare case of Mycophenolate Mofetil - induced PRES in a 43-year-old male patient following allogeneic stem cell transplantation for very severe aplastic anemia.
References
- Sudulagunta SR, Sodalagunta MB, Kumbhat M, Nataraju AS. Posterior reversible encephalopathy syndrome (PRES). Oxf Med Case Reports. 2017;2017(4):omx011. https://doi.org/10.1093/omcr/omx011
[Google Scholar] - Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008;29(6):1036–42. https://doi.org/10.3174/ajnr.A0928
[Google Scholar] - Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914–25. https://doi.org/10.1016/S1474-4422(15)00111-
[Google Scholar] - Hossain MA, Jehangir W, Nai Q, Jessani N, Khan R, Yousif A, et al. Posterior Reversible Encephalopathy Syndrome in a Bone Marrow Transplant Patient: A Complication of Immunosuppressive Drugs? World J Oncol. 2015;6(4):426–8. https://doi.org/10.14740/wjon932w
[Google Scholar] - Zhang L, Xu J. Posterior reversible encephalopathy syndrome (PRES) attributed to mycophenolate mofetil during the management of SLE: a case report and review. Am J Clin Exp Immunol. 2018;7(1):1–7.
- Dai Y, Liu W, Hong F. Post reversible encephalopathy syndrome attributed to mycophenolate mofetil used in the treatment of SLE: A case report and review of literature. J Int Med Res. 2024;52(1):3000605231218620. https://doi.org/10.1177/03000605231218620
[Google Scholar] - Mycophenolate mofetil. Reactions Weekly. 2016;1607:306. https://doi.org/10.1007/s40278-016-18880-3
[Google Scholar] - Gupta M, Aggarwal R. Posterior reversible encephalopathy syndrome associated with mycophenolate mofetil use: a case series. In: American College of Clinical Pharmacy (ACCP) Annual Meeting; 2021. Available from: https://accp.confex.com/accp/ 2021am/mediafile/Handout/Paper58579/ACCP%20Poster%20FIN AL%20PDF.pdf.